Form 4: Relay Therapeutics Director Douglas Ingram Acquires Stock Options

Director Douglas Ingram acquired stock options for 102,225 shares of Relay Therapeutics common stock on June 3, 2024.

Summary

• On June 3, 2024, Douglas Ingram, a director of Relay Therapeutics, Inc., was granted stock options to purchase 102,225 shares of the company's common stock.
• The exercise price of these options is $6.79 per share.
• The options vest in full on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders following the grant date.
• The options expire on June 2, 2034.
• Following the transaction, Ingram directly owns options for 102,225 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, and the acquisition of stock options by a director is generally viewed as a positive, but not significantly so.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, used to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates